-
JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs
Hepatitis flares are common and potentially harmful after stopping NAs, making it essential to identify predictive factors for risk stratification and post-discontinuation follow-up. This multicenter cohort study involved CHB patients…
-
Expert Insights from the 2024 ESMO Congress l The INSPIRE Study Shines on the International Stage Once Again
The European Society for Medical Oncology Congress 2024(ESMO 2024) opened on September 13, in Barcelona,Spain. Lung cancer remains one of the key areas of focus,with several groundbreaking studies presented at the conference. Oncology Frontier invited Dr.Yuankai Shi, principal investigator of the INSPIRE study from the Cancer Hospital Chinese Academy of Medical Sciences,to share the latest…
-
Gut丨MED12 Loss Activates Retrotransposons to Enhance Immunotherapy Sensitivity in Pancreatic Cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, characterized by high mortality rates and limited treatment options. Immunotherapy, particularly immune checkpoint blockade (ICB), has shown remarkable efficacy in treating cancers like melanoma and non-small cell lung cancer. However, many PDAC patients exhibit poor responses to ICB, mainly due to the tumor’s low immunogenicity…
-
Wetland Virus: Chinese Scientists Discover a New Tick-Borne Virus
On September 4, a team of Chinese researchers led by Dr. Wei Liu and Dr. Hao Li from the State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, along with Ningyi Jin’s team from the Changchun Institute of Veterinary Medicine, published a groundbreaking study in the New England Journal of Medicine…
-
SOHO 2024丨Dr. Peihua Lu: CD7 CAR-T Cell Therapy Opens New Pathways to Cure, Reshaping the Future of T-Cell Malignancy Treatment
The 12th Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) took place in Houston, USA, from September 4 to 7, 2024. It brought together leading experts in hematologic oncology from around the world to discuss the latest research findings and explore new treatment strategies. Among the numerous topics discussed, the treatment of T-cell…
-
Dr. Hongmei Jing: A New Era of Precision Medicine in Lymphoma Treatment
With the rapid advancements in medical technology and deeper insights into the mechanisms of lymphoma, traditional chemotherapy is gradually giving way to a new era of precision-targeted and immunotherapies. Innovative drugs are emerging like bamboo shoots after the rain, offering personalized treatment paths tailored to lymphoma patients. This marks the dawn of a new era…
-
EBMT China’s Voice | Professors Xiaoyan Ke and Kai Hu’s Team Present Two Studies Showing Improved Survival in Lymphoma and Multiple Myeloma Patients
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from April 14th to 17th in Glasgow, United Kingdom, showcasing the latest advancements in stem cell transplantation and cell therapy. These advancements are driving better clinical outcomes for patients with hematological diseases and blood cancers. At this year’s conference,…
-
Expert Interview: Professor Chunrui Li Discusses Advancements in CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Multiple Myeloma (MM) is a common hematologic malignancy, and with the emergence of immunotherapy, particularly CAR-T therapy as a revolutionary immunotherapeutic approach, the survival of patients with relapsed/refractory multiple myeloma (R/R MM) has significantly improved. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)…
Connecting Medical Expertise through Media